{"title":"The economic and societal burden associated with Post-COVID in the Netherlands: a cost-of-illness and quality of life study protocol.","authors":"Lieke Maas, Mickael Hiligsmann, Susanne Young, Marcia Spoelder, Marielle Goossens","doi":"10.1080/14737167.2026.2717292","DOIUrl":null,"url":null,"abstract":"<p><p>Post-COVID poses a substantial yet under-quantified burden on the Dutch healthcare system and labor market, lacking detailed data on societal costs and health-related quality of life (HRQOL). This study outlines a cross-sectional, prevalence-based, bottom-up design aimed at mapping individual patient costs and the impact of HRQOL within the Netherlands. Patient data will be further stratified according to context-specific factors such as disease severity and symptom clusters if sufficient data is available. The study collects individual resource-use, productivity and HRQOL data by self-report. Adult (≥18 years) respondents with Post-COVID are recruited nationally via patient platforms and the Post-COVID Network Netherlands (PCNN). The target sample for the quantitative component is ~400 respondents to provide robust descriptive cost and HRQOL estimates and exploratory subgroup descriptions. Resource use is measured primarily with the adapted versions of iMTA Medical Consumption Questionnaire (iMCQ) and iMTA Productivity Cost Questionnaire (iPCQ) and valued using Dutch reference unit prices. HRQOL is measured using the EQ-5D-5L, applying the Dutch tariff. The study results will describe the economic impact of Post-COVID, focusing on cost-of-illness (€) and HRQOL (utilities) in the Netherlands. The study follows national data-protection procedures and aims to inform policy, care organization and future economic evaluations.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-5"},"PeriodicalIF":2.2000,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2026.2717292","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Post-COVID poses a substantial yet under-quantified burden on the Dutch healthcare system and labor market, lacking detailed data on societal costs and health-related quality of life (HRQOL). This study outlines a cross-sectional, prevalence-based, bottom-up design aimed at mapping individual patient costs and the impact of HRQOL within the Netherlands. Patient data will be further stratified according to context-specific factors such as disease severity and symptom clusters if sufficient data is available. The study collects individual resource-use, productivity and HRQOL data by self-report. Adult (≥18 years) respondents with Post-COVID are recruited nationally via patient platforms and the Post-COVID Network Netherlands (PCNN). The target sample for the quantitative component is ~400 respondents to provide robust descriptive cost and HRQOL estimates and exploratory subgroup descriptions. Resource use is measured primarily with the adapted versions of iMTA Medical Consumption Questionnaire (iMCQ) and iMTA Productivity Cost Questionnaire (iPCQ) and valued using Dutch reference unit prices. HRQOL is measured using the EQ-5D-5L, applying the Dutch tariff. The study results will describe the economic impact of Post-COVID, focusing on cost-of-illness (€) and HRQOL (utilities) in the Netherlands. The study follows national data-protection procedures and aims to inform policy, care organization and future economic evaluations.
期刊介绍:
Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.
The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.